Every minute matters...
reversal agent for PRADAXA1
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.1
*Accurate as of 12/29/2017.
References: 1. PRAXBIND [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
Revised 12/2017: PC-PB-0141-PROF-R1